(Date:1/8/2009)...re/ -- Amira Pharmaceuticals, a small molecule pha...arly development of compounds to treat inflammator... Paul Anderson, Professor Jerold Chun and Professo...his further strengthens the Board that includes Pr... Inflammatory diseases, Harvard Medical School ),...
(Date:1/8/2009)...ire/ -- Sonoma is known for delicious food, great,... also be known for inventive,beef recipes. The 2... in late,September, during the peak of the area,s...k competition and a Chef/Media Challenge. Home co... chefs working in the San Francisco Bay Area,and ...
(Date:1/8/2009)...Newswire-USNewswire/ -- Visitors to this year,s Pe...u shots and other helpful resources by stopping at..., , "Pennsylvania,s flu season got off to a rela...he rise. Getting a flu shot now is the best way to...ss," said acting Secretary of Health Everette Jame...
(Date:1/8/2009)...and can lead to severe depression yet pain is wid...ded as ,normal, in later life. Now a new study fro...le,s experiences of pain and how best Government, ...ssue. , The report, Pain in older people: refle...pective , aims to highlight the issue of pain in o...
Breaking Medicine News(10 mins):Health News:Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager 2Health News:Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager 3Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 2Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 3Health News:A life with pain -- new study examines the experiences of older people 2Health News:A life with pain -- new study examines the experiences of older people 3Health News:A life with pain -- new study examines the experiences of older people 4...tive tooth at some point of their life. A visit to...n out' or 'you brush in a hard way, so your teeth ...versity have come out with a solution that could m...researchers have developed a solution which they c...
...IVF) baby of a single parent has been born in a ci...egal status and the single father's parenthood rig...ad ended in divorce years ago, is apparently the c...r whose son was born through IVF method this Sunda...
...tal imaging focus on modalities such as (MRI). The...abies and newborns with MR imaging that uses no io...ment of many // disorders that were previously und...etal MRI is usually performed when ultrasound is i...
... have found a new combination drug for combating P... causing malaria. They used a combination of Chlor...lling P. falciparum which is resistant to Chloroqu...d drug in the treatment of malaria since 1950s. Ch...
Other Medicine News:Health News:A first for India - IVF baby born of surrogacy 2(Date:1/6/2009)... Cequent Pharmaceuticals, a pionee...RNAi-based treatments to prevent and treat human d...mpleted a successful toxicology study of its candi...peutic targeting the primary oncogene (beta-cateni.... FAP is an inherited gastrointestinal disease tha...
(Date:1/5/2009)...5 Micromet, Inc.,(Nasda...g novel, proprietary,antibodies for the treatment...,provides an outlook on key events anticipated for...vide an update on its research and development,pr...12 to 16, 2009: Update on several preclinical BiTE...
(Date:12/29/2008)...PRNewswire-USNewswire/ -- The winner of the 2008 A...as announced today by Dr. Peter G. Goldschmidt, Pr...itute. , , The winner of the annual award was ...enter -- for its best practice " IND Regulatory ...r 1) enhanced human subjects protection, 2) improv...
(Date:12/17/2008)... development and validation of non-animal alternat...7 MatTek Corporation today announc...SAC) endorsed the scientific validity of the Modif...mber meeting. ESAC concluded that the Modified Ep...for the prediction of skin irritating and non-irri...
Breaking Medicine Technology:Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 52008 Human Research Protection Award Recipients Announced 2EpiDerm's Skin Irritation Test Fully Validated in European Union 2Patients with chronic illness benefit from telehealth intervention 18715 1Patients with chronic illness benefit from telehealth intervention 18715 2IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 1IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 2Nektar Therapeutics Announces First Quarter 2008 Results 18712 1Nektar Therapeutics Announces First Quarter 2008 Results 18712 2Nektar Therapeutics Announces First Quarter 2008 Results 18712 3Nektar Therapeutics Announces First Quarter 2008 Results 18712 4Nektar Therapeutics Announces First Quarter 2008 Results 18712 5Nektar Therapeutics Announces First Quarter 2008 Results 18712 6Nektar Therapeutics Announces First Quarter 2008 Results 18712 7Nektar Therapeutics Announces First Quarter 2008 Results 18712 8Webcast Alert 3A Medial Saude S A Announces First Quarter 2008 Earnings Conference Call Webcast 18709 1... by 33% 3.5 Years Post Surgery, VIENNA, Va., May 2...ION announced today that its cancer drug Multikine...overall survival in a,Phase II study of head and n...y 20, 2007 at the First International Congress of,...Amsterdam, the,Netherlands, by Dr. Eyal Talor, Sen...
...estive Disease Week -, CAMBRIDGE, Mass., May 21, 2...resentation of data from a Phase 2 study in which,...ed bowel function,in patients with constipation- p... data also showed linaclotide was well tolerated w... is a first-in-class,compound currently being deve...
Other Medicine Technology:CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 2CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Each handle is designed to fit a specific trephine size.
Reusable, stainless steel trephine with handle.
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons.
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons.
Medicine Products: